The original success of the copyright undeniably revolutionized the pharmaceutical landscape, but betting in companies primarily reliant on generic versions presents a complex picture. While early returns were impressive, the expiration of patents and the rise of cheaper alternatives have weakened market share. Therefore, a thorough analysis of cur